SCHEMBL19323950

SCHEMBL19323950

CCC(=O)NC(CO)c1ccccn1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.49
CYP1A2 P05177 2/20 0.49
KDM4E B2RXH2 1/20 0.46
TACR3 P29371 2/20 0.43
GAA P10253 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
MAPK1 P28482 5/20 0.42
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
TP53 P04637 1/20 0.42
HSD17B10 Q99714 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.41
KCNA5 P22460 2/20 0.40
CYP3A4 P08684 2/20 0.40
KCNJ5 P48544 1/20 0.40
KCNJ3 P48549 1/20 0.40
SCN5A Q14524 1/20 0.40
KCND3 Q9UK17 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24015882 0.84 ALDH1A1 (0.44) ALDH1A1CYP1A2KDM4ETACR3GAA
SCHEMBL19322907 0.84 ALDH1A1 (0.44) ALDH1A1CYP1A2KDM4ETACR3GAA
SCHEMBL24015880 0.84 ALDH1A1 (0.44) ALDH1A1CYP1A2KDM4ETACR3GAA
SCHEMBL11368716 0.84 ALDH1A1 (0.49) ALDH1A1CYP1A2KDM4ETACR3SMN1; SMN2
SCHEMBL27228935 0.83 ALDH1A1 (0.45) ALDH1A1CYP1A2KDM4ETACR3GAA
SCHEMBL13157233 0.81 PARP1 (0.52) ALDH1A1CYP1A2KDM4EGAASMN1; SMN2
SCHEMBL20919515 0.81 PARP1 (0.52) ALDH1A1CYP1A2KDM4EGAASMN1; SMN2
SCHEMBL12975784 0.81 PARP1 (0.52) ALDH1A1CYP1A2KDM4EGAASMN1; SMN2
SCHEMBL19318488 0.81 RIPK1 (0.47) ALDH1A1CYP1A2KDM4ETACR3GAA
SCHEMBL25587524 0.81 RIPK1 (0.47) ALDH1A1CYP1A2KDM4ETACR3GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170253614-A1 HEPATITIS C VIRUS INHIBITORS AND USES THEREOF IN PREPARATION OF DRUGS CHANGZHOU YINSHENG PHARMACEUTICAL CO., LTD. (CN) 2017-09-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170253614-A1 HEPATITIS C VIRUS INHIBITORS AND USES THEREOF IN PREPARATION OF DRUGS HAVCR2, HCCS, LIPC ALDH1A1 1148/4885CYP1A2 472/4885KDM4E 3963/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.